U.S. Arm Of Indian Glenmark Settles Patent Suits With Teva
This article was originally published in PharmAsia News
Executive Summary
The U.S. subsidiary of India's Glenmark Pharmaceuticals and Israel's Teva have settled a patent dispute in a U.S. court involving Teva's Coreg (carvedilol) for treating congestive heart failure. Glenmark Generics had used a process patent to prepare the compound, sparking a suit by Teva, and Glenmark responded with a challenge of its own against two Teva patents for Coreg. The two companies settled their disputes out of court and the judge in the case accepted. Two other Indian drug makers, Ranbaxy and Dr. Reddy's, earlier settled out of court with Teva over the same drug. (Click here for more
You may also be interested in...
Armed With Three New Compounds, Glenmark Readies for More Out-licensing Opportunities
MUMBAI - Braving a tough economic environment, India's Glenmark Pharmaceuticals is ramping up its line-up of early-stage compounds with the aim of licensing them out to interested multinational companies
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.